North America Vaccine Adjuvant Market

North America Vaccine Adjuvant market size (2023 to 2028)

The size of the Vaccine Adjuvant Market in North America is estimated to be growing at a CAGR of 10.3% from 2023 to 2028. The market is estimated to be worth USD 354.7 million by 2028 and USD 217.3 million in 2023. 

North America is dominating the adjuvant vaccine market globally. Growth in the North American segment is mainly driven by the fast-increasing elderly population and rising government funding in North American countries.

Vaccine adjuvants benefit in improving novel and advanced vaccines, which was not probable earlier due to less effectiveness of a vaccine using the only antigen. Adjuvants are progressively used to advance harmless and effective vaccines as they create healthy, long-lasting defensive immune responses with a high edge of safety against infections. 

This market is primarily driven by the increasing prevalence of diseases such as allergy, cancer, and HIV/AIDS, rising demand for innovative treatment options, and improvement of enhanced vaccine immunization. In addition, the upsurge in alliances and acquisitions by private organizations and augmented funding by government bodies for research and development are also expected to drive market growth.

The primary factor hindering the growth of the North American adjuvant vaccine market is stringent regulation for new vaccines.

This research report on the North American vaccine adjuvant market has been segmented and sub-segmented into the following categories:

By Type: 

• Aluminum Salts
• Tensoactive Adjuvants
• Adjuvant Emulsions
• Bacteria Derived Adjuvants
• Liposome Adjuvants
• Carbohydrate Adjuvants

By Route Of Administration: 

• Oral
• Intradermal
• Subcutaneous
• Intranasal
• Intramuscular

By Mechanism Of Action: 

• Immune Stimulants
• Carriers
• Vehicle Adjuvants

By Country: 

• The United States
• Canada
• The Rest of North America

Regionally, the USA led the North American region due to increasing awareness regarding vaccines, followed by Canada.

The U.S. vaccine adjuvant market is driven by the continued use of aluminum salt vaccine adjuvant for the last three decades in the market. In 2021, the National Institute of Infectious Allergy and Infectious Diseases had taken the initiative to develop advanced vaccine adjuvant for the better use of tuberculosis and non-HIV infectious disease in the United States. The presence of prominent critical players in this region is influencing the growth of the market. The high prevalence of chronic and acute disorders in the US is propelling the growth of the adjuvant vaccine market. Recently, private and government funding collaboration to develop innovative vaccine adjuvants to combat viruses will boost the market.

The Canadian vaccine adjuvant market is anticipated to grow at a robust CAGR during the forecast period in the North American market. The Canadian government has more funding to develop an immune response and immune safety in this pandemic situation. There are 2561 HIV diagnoses in Canada, with an increasing rate of 8.2% compared to the previous year. Also, the rising prevalence of cancer and infectious disease in the region is estimated to drive the Canadian vaccine adjuvant market further. The presence of healthcare facilities and innovation in drug discovery is fuelling the growth of the Canadian vaccine adjuvant market.

KEY MARKET PLAYERS:

Companies playing a dominant role in the North America vaccine adjuvant market profiled in this report are MPV Technologies, Avanti Polar Lipids, Novavax Inc. Brenntag Biosector, SEPPIC, Agenus, Inc., Invivogen, SPI Pharma, Inc., CSL Limited, and OZ Biosciences.